210 related articles for article (PubMed ID: 18067006)
21. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.
Colombo M; Mirandola L; Platonova N; Apicella L; Basile A; Figueroa AJ; Cobos E; Chiriva-Internati M; Chiaramonte R
Leukemia; 2013 Apr; 27(5):1009-18. PubMed ID: 23307030
[TBL] [Abstract][Full Text] [Related]
22. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
Ehrlich LA; Chung HY; Ghobrial I; Choi SJ; Morandi F; Colla S; Rizzoli V; Roodman GD; Giuliani N
Blood; 2005 Aug; 106(4):1407-14. PubMed ID: 15878977
[TBL] [Abstract][Full Text] [Related]
23. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
25. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
26. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
27. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
28. New insights in myeloma-induced osteolysis.
Barillé-Nion S; Bataille R
Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
[TBL] [Abstract][Full Text] [Related]
29. The pathogenesis of the bone disease of multiple myeloma.
Edwards CM; Zhuang J; Mundy GR
Bone; 2008 Jun; 42(6):1007-13. PubMed ID: 18406675
[TBL] [Abstract][Full Text] [Related]
30. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease.
Silvestris F; Cafforio P; Tucci M; Grinello D; Dammacco F
Br J Haematol; 2003 Jul; 122(1):39-52. PubMed ID: 12823344
[TBL] [Abstract][Full Text] [Related]
33. The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R
Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
[TBL] [Abstract][Full Text] [Related]
34. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.
Reagan MR; Mishima Y; Glavey SV; Zhang Y; Manier S; Lu ZN; Memarzadeh M; Zhang Y; Sacco A; Aljawai Y; Shi J; Tai YT; Ready JE; Kaplan DL; Roccaro AM; Ghobrial IM
Blood; 2014 Nov; 124(22):3250-9. PubMed ID: 25205118
[TBL] [Abstract][Full Text] [Related]
35. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
36. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
Clines GA; Mohammad KS; Bao Y; Stephens OW; Suva LJ; Shaughnessy JD; Fox JW; Chirgwin JM; Guise TA
Mol Endocrinol; 2007 Feb; 21(2):486-98. PubMed ID: 17068196
[TBL] [Abstract][Full Text] [Related]
37. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
[TBL] [Abstract][Full Text] [Related]
38. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
39. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
40. The osteoblastic niche in the context of multiple myeloma.
Toscani D; Bolzoni M; Accardi F; Aversa F; Giuliani N
Ann N Y Acad Sci; 2015 Jan; 1335():45-62. PubMed ID: 25424768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
